Trial Profile

A Phase II Study of Nimotuzumab in Patients with Unresectable Stage III Non-small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nimotuzumab (Primary) ; Cisplatin; Vinorelbine
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Daiichi Sankyo Company

Most Recent Events

23 Sep 2011 Interim results to be reported at a scientific conference in the third quarter of 2011, according to a YM BioSciences media release
10 Feb 2011 Daiichi Sankyo advised YM BioSciences that recruitment completed and data expected in the first half of 2011, according to a YM BioSciences media release
11 Nov 2010 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com